Given these findings and the similar Hct levels between the patients with and without diabetes, the observed increases in erythropoietin dosage and the Hct levels from below 30% to above 30% might benefit peritoneal dialysis patients with diabetes in terms of reducing the cardiovascular risk but would have no impact on the cardiovascular risk of patients without diabetes. This evidence concerns the gene EPO and diabetes mellitus.